Charles River Laboratories Intl. Inc vs Main Street Capital Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while Main Street Capital Corporation trades at $53.31 (market cap $4.94B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.25% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MAIN | |
|---|---|---|
Market Cap | $11.14B | $4.94B |
Sector | Health | Financials |
52-Week High | $233.60 | $67.54 |
52-Week Low | $145.57 | $49.63 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 8.25% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Main Street Capital (MAIN) trades at $52.51, down 0.62% on the day, with a bullish technical signal from moving averages. The company reported a net income margin of 81.08% for 2025, though revenue dipped to $592M from $601M in 2024. Recent news highlights MAIN's premium valuation among internally managed BDCs and a consistent dividend history, with the latest quarterly earnings showing a mix of beats and misses against expectations.
The outlook is supported by a consensus price target of $57.75, implying upside, but risks include softening earnings and negative operating cash flow. The stock offers a high yield, but investors should weigh the sustainability of dividends against rising expenses and a higher share count noted in recent analysis.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →